A recent closed meeting about building synthetic genomes raised suspicions about just what scientists were planning, away from the public eye.
Monsanto an other biotech companies got caught short in the 1990s. But since then, the GM argument has been moving in their direction.
Why are half of European Union members opting out of GMO crops? Hint: it's not about food and environmental safety.
A toddler from London has had gene therapy for leukaemia and it seems to have worked. But why have breakthroughs taken so long?
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
New EU rules on GM attempt to unblock logjam that has hung over the technology in the region for most of this century. To work, anti-GM member states and Big Biotech will need to cooperate.